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A B S T R A C T
The inﬂuenza A virus (IAV)–cytokine–trypsin/matrix metalloproteinase-9 (MMP-9) cycle is one of the important
mechanisms of multiple organ failure in severe inﬂuenza. Clarithromycin, a macrolide antibiotic, has immune
modulatory and anti-inﬂammatory eﬀects. We analyzed the eﬀects of clarithromycin on the induction of che-
mokines, cytokines, MMP-9, trypsin, vascular hyper-permeability and inﬂammatory aggravation in mice with
IAV infection. IAV/Puerto Rico/8/34(H1N1) infection increased the levels of monocyte chemoattractant protein-
1 (MCP-1) and cytokines in serum, and MMP-9 and trypsin in serum and/or the lungs and heart. Clarithromycin
signiﬁcantly suppressed the induction of serum MCP-1 and MMP-9 and vascular hyperpermeability in these
organs in the early phase of infection, but did not suppress the induction of trypsin, IL-6 or IFN-γ.
Histopathological examination showed that clarithromycin tended to reduce inﬂammatory cell accumulation in
the lungs and heart. These results suggest that clarithromycin suppresses infection-related inﬂammation and
reduces vascular hyperpermeability by suppressing the induction of MCP-1 and MMP-9.
1. Introduction
Inﬂuenza A virus (IAV) is the most common infectious pathogen in
humans and causes signiﬁcant morbidity and mortality, particularly in
infants and the elderly population [1,2]. Multiple organ failure (MOF)
with vascular hyperpermeability is reported in the progressive stage of
seasonal inﬂuenza virus pneumonia, particularly in patients with un-
derlying risk factors [3] and is also common in infection with the highly
pathogenic avian inﬂuenza viruses [4]. We reported previously that the
“inﬂuenza–cytokine–trypsin/matrix metalloprotease-9 (MMP-9)” cycle
is one of the key pathogenic mechanisms that interact with IAV mul-
tiplication, vascular hyperpermeability and MOF in severe inﬂuenza
[5–8].
Marked increases in the levels of proinﬂammatory cytokines, such
as tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and inter-
leukin-1β (IL-1β) (i.e., cytokine storm) aﬀect cell adhesion, perme-
ability, apoptosis, mitochondrial energy metabolism and reactive
oxygen species, and can potentially result in vascular dysfunction, hy-
perpermeability and MOF [9,10]. These cytokines upregulate cellular
trypsin [5–8] and MMP-9 through the activation of nuclear factor-
kappa B (NF-κB) and activator protein 1 (AP-1) [11,12]. Induced and
secreted trypsin potentiates viral entry and replication in various organs
and vascular endothelial cells, because IAV has no viral hemagglutinin
processing protease in its genes and post-transcriptional hemagglutinin
cleavage by cellular trypsin-type proteases is indispensable for viral
membrane fusion activity, virus entry into cells and multiple replication
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cycles [7,13–15]. In addition, secreted trypsin induces cytokine release
via proteinase-activated receptor (PAR)-2 [16] and also plays a role in
blood-brain barrier (BBB) destruction by increasing intracellular cal-
cium concentrations and loss of tight-junction protein, zonula occlu-
dens-1, via PAR-2 [5]. Furthermore, the secreted trypsin eﬃciently
converts proMMPs to active MMPs [18,19]. Among the activated
MMPs, upregulation of MMP-9 promotes endothelial hyperpermeability
and enhances inﬂammatory cell migration through the degradation of
type IV collagen in the vascular basement membrane [17,20].
There is growing evidence that macrolides with a 14-member ring,
such as erythromycin and clarithromycin, are bifunctional drugs; they
have an anti-inﬂammatory [21–24] and immune-modulatory properties
[25–28], in addition to their antimicrobial eﬀects. We reported pre-
viously that clarithromycin enhances secretory IgA production and its
neutralizing activities through the induction of IgA class switching re-
combination and upregulation of B-cell-activating factor of the tumor
necrosis factor family molecule in mucosal dendritic cells as an ad-
juvant or immunomodulatory compound in IAV-infected mice [28].
Thus, oral administration of clarithromycin in pediatric patients with
inﬂuenza enhanced anti-viral mucus and systemic immunity and re-
duced the re-infection rate in the subsequent year [27]. While previous
studies described the immunomodulatory eﬀects of clarithromycin
[26–28], the anti-inﬂammatory eﬀects of clarithromycin on vascular
hyperpermeability in the pathogenesis of MOF in severe inﬂuenza are
not fully understood.
Vascular permeability is controlled by a “barrier” comprised of the
micro-vascular wall, which includes the endothelial glycocalyx, en-
dothelium, basement membrane, and all accessory cells wrapped
around the outer surface of the vessel [29]. Though each of these
components contributes to vascular wall permeability, we focused on
disruption of the basement membrane and up-regulation of MMP-9,
since MMP-9 is one of the important factors in the cycle of “inﬂuen-
za–cytokine–trypsin/MMP-9” described above.
The present study was conducted to determine the anti-in-
ﬂammatory eﬀects of clarithromycin on the induction of MMP-9, cy-
tokines and chemokines in serum, and MMP-9, trypsin, vascular hy-
perpermeability and pathological changes in the lungs and heart of
mice infected with IAV.
2. Materials and methods
2.1. Animals and virus infection
Four-week-old Balb/c female mice just after weanling were pur-
chased from Japan SLC (Shizuoka, Japan) and used in all experiments.
Inﬂuenza A/Puerto Rico/8/34(H1N1) (PR8) was kindly provided by
The Research Foundation for Microbial Diseases of Osaka University
(Kagawa, Japan). All animal experiments were conducted in ac-
cordance with the Guide for the Care and Use of Laboratory Animals
(NIH Publication No. 85-23, 1996), and the study was approved by the
Tokushima University Animal Research Ethics Committee (#T27-37).
Under ketamine and xylazine anesthesia, we administrated in-
tranasally 25 plaque-forming units (pfu) of PR8 in 15 μl of saline, which
induces cytokine storm but does not cause death up to post-infection
day 9 (PID-9). Saline alone was instilled intranasally in the control
mice. Immediately after infection, each group of animals were treated
orally with a solution of clarithromycin at 150 μg/head in 100 μl me-
thyl cellulose (MC) or MC as the vehicle every 12 h for 9 days.
2.2. Histological analysis
The isolated perfused lungs and heart of each group of animals
(n= 3) were ﬁxed with 10% buﬀered formalin, pH 7.2, and then em-
bedded in paraﬃn. The paraﬃn blocks were cross-sectioned at 5 μm
thickness using microtome (Leica Instruments, Nusslosh, Germany).
The sections were subjected to hematoxylin-eosin staining (H&E
staining). Microscopic images of the cranial lobe of the right lung and
heart were acquired with an all-in-one Fluorescence Microscope (BZ-
X710; Keyence Corporation, Osaka, Japan). Evans’ blue-treated tissue
sections were also analyzed by a Fluorescence Microscope BZ-X710.
The hypercellular areas with inﬁltrating inﬂammatory cells (shown in
red) and the hypocellular areas (shown in green) in three diﬀerent areas
of the lung and heart of each animal were quantiﬁed by BZ-X analyzer
software (Keyence Corporation), as described previously [31,32], and
presented as percentages of the hypercellular area in the lung and heart
section areas.
2.3. Evans’ blue treatment
To examine changes in vascular permeability in the lungs and heart
during the early phase of IAV infection, each non-infected and infected
mouse (n= 3) received intraperitoneal injection of 0.2% Evans’ blue in
100 μl of phosphate-buﬀered saline (PBS) on post-infection days (PIDs)
3, 6 and 9, as described previously [30]. One hour after the injection,
the entire body was perfused through the left ventricle with 30 ml of
saline, and the heart and lungs were excised. The tissues were homo-
genized with 500 μl of saline, and then centrifuged at 6000 × g for
20 min at 4 °C to collect the supernatant. The concentration of Evans’
blue dye in the supernatant was measured at a wavelength of 590 nm
with a SPECTRA max PLUS (Molecular Devices, Sunnyvale, CA).
2.4. Western immunoblotting
The lungs and heart of each group of animals treated with clari-
thromycin or MC (n= 5) were homogenized with extraction buﬀer
containing 50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 10% glycerol, 1%
NP 40, 0.5% deoxycholate, 0.4 mM EDTA, and 0.5 mM sodium ortho-
vanadate, and centrifuged at 12,000 × g for 20 min at 4 °C. The protein
concentration of the supernatant was measured by a BCA assay kit
(Thermo Scientiﬁc, Rockford, IL), according to the protocol provided by
the manufacturer. Sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE) was carried out using 10–20% gradient gels
(Multigel II mini, COSMO BIO, Tokyo, Japan) under reducing condi-
tions. Proteins separated by SDS-PAGE were transferred onto a poly-
vinylidene diﬂuoride membrane (Millipore, Bedford, MA) and in-
cubated overnight with anti-MMP-9 or anti-β-actin antibodies at 4 °C.
After washing, the membranes were incubated with peroxidase-con-
jugated anti-mouse (Invitrogen, Carlsbad, CA) or −rabbit (Sigma, St.
Louis, MO) IgG antibodies for one hour at room temperature, and
proteins were detected using enhanced chemiluminescence detection
reagent (GE Healthcare Biosciences, Uppsala, Sweden).
2.5. Enzyme-linked immunosorbent assay (ELISA)
Blood samples collected from the mouse heart of each group of
animals treated with clarithromycin or MC (n= 5) were centrifuged at
2000 × g for 10 min at 4 °C and the serum was used for measurement of
MMP-9, tissue inhibitor of metalloproteinase-1 (TIMP-1), monocyte
chemoattractant protein-1 (MCP-1), macrophage inﬂammatory protein
1α (MIP-1α), IL-6, interferon-γ (IFN-γ), and TNF-α by ELISA kits (R&D
Systems, Minneapolis, MN), using the method recommended by the
manufacturer. The isolated lungs and heart were minced and homo-
genized with 30 vols of PBS, and then centrifuged at 12,000 × g for
20 min at 4 °C to collect the supernatant for measurement of MMP-9
and trypsin levels. Trypsin levels were measured with mouse Trypsin
ELISA kit (MyBioSource, San Diego, CA) according to the protocol
provided by the manufacturer.
2.6. Statistical analysis
The results are expressed as mean ± standard deviation (SD).
Diﬀerences between groups were examined using Student’s t-test. P
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values< 0.05 were considered signiﬁcant. All statistical analyses were
performed using Microsoft Excel (Microsoft, Redmond, WA).
3. Results
3.1. Eﬀects of clarithromycin on cytokines and chemokines in serum of mice
infected with PR8
Since the cytokine family in the “inﬂuenza–cytokine–trypsin/MMP-
9” cycle is largely involved in the pathological changes and vascular
hyperpermeability in severe IAV infection, we measured the levels of
various cytokines and chemokines in the serum of infected mice.
Immediately after viral infection with nasal instillation of PR8, each
mouse was treated orally with clarithromycin or the vehicle twice daily
for 9 days. Changes in body weight of these mice were monitored till
the end of the study. While all infected animals survived to PID-9, the
body weight decreased to 75.3% and 74.7% of no infection control in
MC- and clarithromycin-treated mice, respectively (Fig. 1), indicating
that clarithromycin by itself has no signiﬁcant toxicity during the ex-
perimental period.
Under the experimental conditions described above, the levels of
MCP-1 and IL-6 in serum started to increase at PID-3 and then gradually
decreased until PID-9, while those of IFN-γ transiently increased at PID-
6 (Fig. 2). Inﬂuenza A virus infection-induced increase in MCP-1, which
guides the migration and inﬁltration of monocytes/macrophages to
inﬂammation sites, was signiﬁcantly suppressed by clarithromycin at
PID-6, and also tended to be suppressed, though not signiﬁcantly, until
PID-9. However, clarithromycin had no signiﬁcant eﬀect on the up-
regulation of IL-6 and IFN-γ in serum of mice after IAV infection. The
serum levels of the other cytokines and chemokines, such as TNF-α and
MIP-1α, in mice infected with IAV were below the detection limits
throughout the experiment (data not shown).
3.2. Clarithromycin reduces spread of inﬂammation and inﬂammatory cell
accumulation in the lungs and heart of IAV-infected mice
Histopathological evaluation of the lungs of MC-treated infected
mice by H&E staining showed the presence of inﬂammatory cells at
PID-3, and further accumulation with time after infection, not only in
the bronchi and alveolar walls but also in arterial and venous areas,
resulting in abnormal thickening, hence, the strong staining with he-
matoxylin (Fig. 3a, upper panel). Damaged alveolar structure was de-
tected at PIDs 6 and 9. However, mild distribution and limited accu-
mulation of inﬂammatory cells was noted in the lungs of infected mice
treated with clarithromycin. Histological quantiﬁcation of the percen-
tage of the red-colored hypercellular area in the lungs showed sup-
pression of inﬂammatory cell accumulation in clarithromycin-treated
mice, compared with MC-treated mice at PIDs 6 and 9, although the
diﬀerences between the two were not statistically signiﬁcant (Fig. 3a,
lower panel).
A similar eﬀect for clarithromycin was noted in the heart (Fig. 3b).
In the MC-treated mice, inﬁltrated inﬂammatory cells appeared initially
in the subepicardium at PID-3, followed by extensive inﬁltration across
the interstitium and perivascular areas deep into the myocardium, ac-
companied by progressive destruction of the extracellular matrix after
IAV infection. Treatment with clarithromycin tended to reduce the area
and extent of inﬂammatory cell accumulation in the heart of IAV-in-
fected mice, relative to MC treatment, during IAV infection with a
signiﬁcant diﬀerence at PID-3 (Fig. 3b, lower left panel).
3.3. Clarithromycin attenuates vascular hyperpermeability in the lungs and
heart of IAV-infected mice
Extravasation of Evans’ blue examined by ﬂuorescence microscopy
showed increased vascular permeability in the lung (Fig. 4a) and cor-
onary arteries (Fig. 4b) at PID-3, with gradual worsening with time
after infection until PID-9. Treatment with clarithromycin tended to
suppress Evans’ blue extravasation in the lungs and heart. Quantitative
analysis of Evans’ blue dye levels in the supernatants of heart and lung
homogenates showed signiﬁcant suppression of IAV infection-induced
Evans’ blue extravasation at PID-6 in the lungs and at PID-3 and−6 in
the heart (Fig. 4c). These results showed that clarithromycin induced
suppression of vascular hyperpermeability in the early phase of IAV
infection (at PID-3 and/or−6, but not at PID-9) in the lungs and heart.
Fig. 1. Eﬀects of clarithromycin (CAM) on changes in body weight of mice infected with
IAV PR8. Changes in body weight of infected mice treated with CAM, vehicle MC and
non-infected mice (n= 5). Data are mean ± SD.
Fig. 2. Eﬀects of clarithromycin (CAM) on induction of chemokines and cytokines in
serum of mice after PR8 infection. MCP-1 (top), IL-6 (middle) and IFN-γ (bottom) levels in
serum determined by ELISA at PID-3, −6 and −9 of infected mice treated with CAM,
vehicle MC and non-infected mice (n= 5). Data are mean ± SD. **P < 0.01 versus MC
(by Student’s t-test). No-infection, no infection control at day 0.
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3.4. Clarithromycin suppresses increase in MMP-9 levels in serum and tissue
extracts of IAV-infected mice
Inﬂuenza A virus infection-induced up-regulation of MMP-9 is one
of the key factors involved in increased vascular permeability [5–9].
Accordingly, we measured the eﬀects of clarithromycin on MMP-9 up-
regulation in serum and tissues during the 9-day course of IAV infec-
tion. Clarithromycin signiﬁcantly suppressed the marked increase in
serum MMP-9 levels at PID-3, as monitored by ELISA, and also tended
to suppress the level, though not signiﬁcantly, at PID-6 and −9
(Fig. 5a). In addition, western immunoblotting showed that clari-
thromycin signiﬁcantly suppressed the activated MMP-9 levels in the
heart and lungs of IAV-infected-mice at PID-6 (Fig. 5b).
3.5. Clarithromycin has no eﬀect on trypsin levels in the lungs and heart,
and TIMP-1 levels in serum
Trypsin plays an important role in IAV multiplication in vivo
[7,8,13] and also eﬃciently converts proMMPs to active MMPs
[6,19,21]. In the MC-treated mice, lung trypsin levels increased gra-
dually after infection and reached peak levels during PID-3 to−6 then
decreased at PID-9 (Fig. 6a). Clarithromycin had no signiﬁcant eﬀect on
lung trypsin levels. Furthermore, clarithromycin did not change the up-
regulated trypsin levels in the heart (data not shown). Next, we ana-
lyzed the eﬀect of clarithromycin on levels of MMP-9 inhibitor, TIMP-1,
in serum. TIMP-1 levels increased markedly and continuously after IAV
infection through PID-9 while clarithromycin had no eﬀect on the levels
(Fig. 6b).
4. Discussion
Multiple organ failure with vascular hyperpermeability is the pro-
gressive stage of inﬂuenza virus pneumonia [4,33]. We reported pre-
viously that severe IAV infection was associated with increased in-
tracellular calcium levels and loss of tight junction constituent, zonula
occludens-1, through the upregulation of cytokines and trypsin [5] and
also with glycogen synthase kinase-3β-mediated β-cathenin degrada-
tion in adherens junctions [34]. In addition to the impairment of tight
junction and adherens junction, IAV infection induces degradation of
extracellular matrix by MMPs and trypsin, thus further increasing
vascular hyperpermeability. Taken together, these ﬁndings add support
to the “inﬂuenza–cytokine–trypsin/MMP-9” hypothesis, and that it
could be one of the key mechanisms of vascular hyperpermeability and
MOF in severe inﬂuenza [5,7]. In the present study, we investigated the
anti-inﬂammatory eﬀects of clarithromycin on MMP-9 upregulation
associated with IAV infection, which may play a role in endothelial
hyperpermeability and inﬂammatory cell migration.
It is not uncommon in Japan to prescribe clarithromycin combined
with antiviral neuraminidase inhibitors to prevent complications and
aggravation of the ﬂu symptoms. In this regard, we reported previously
that oral administration of clarithromycin enhances airway mucosal
immunity through the induction of IgA class switching recombination
[28] and signiﬁcantly reduces the re-infection rate in the subsequent
year in pediatric patients with inﬂuenza treated with anti-viral neur-
aminidase inhibitors [27]. In addition to the remarkable im-
munomodulatory eﬀects of clarithromycin, we evaluated here the anti-
inﬂammatory properties of clarithromycin in the lungs and heart of
IAV-infected mice.
Fig. 3. Eﬀects of clarithromycin (CAM) on changes in inﬂammatory cell accumulation in the lungs and heart of mice infected with PR8. Sections from the lungs (a, top panels) and heart
(b, top panels) were stained with hematoxylin-eosin (H&E), and evaluated for tissue inﬂammation and inﬂammatory cell accumulation. The hypercellular areas with inﬂammatory cell
accumulation shown in red and the hypocellular areas shown in green were quantiﬁed using BZ-X analyzer software (bottom right panels). Photographs are representative sections of the
lung and heart of mice of each group (n= 3). Arrowheads: loci of inﬂammatory cell accumulation. Scale bars, 300 μm (a), 100 μm (b). The percentage of the hypercellular area in the
three diﬀerent areas of the lung and heart sections was analyzed using BZ-X analyzer software (a and b, bottom left panels). Data are mean ± SD. *P < 0.05 versus MC (by Student’s t-
test). (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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Fig. 4. Clarithromycin (CAM) suppresses Evans’ blue extravasation in the lungs and heart of mice infected with PR8. Evans’ blue extravasation in lung (a) and heart (b) sections was
analyzed by ﬂuorescence microscopy. Arrowheads: sites of Evans’ blue extravasation. Scale bars, 300 μm (a), 100 μm (b). Photographs are representative sections of the lung and heart of
mice of each group (n= 3). (c) Evans’ blue levels in the supernatants of the lungs and heart homogenates of mice of each group. Data are mean ± SD. No-infection, no infection control
at day 0. *P < 0.05, **P < 0.01, versus MC (by Student’s t-test). (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this
article.)
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Our results showed that IAV infection rapidly induced MCP-1 in
serum at PID-3 and the levels were sustained until PID-9 (Fig. 2), which
is one of the key chemokines known to stimulate the migration and
inﬁltration of monocytes/macrophages [35]. MCP-1 induction was as-
sociated with increased MMP-9 levels in the lungs and heart during PID-
3 to −6, followed by gradual decrease in the levels (Fig. 5b). MMP-9
levels also increased in serum with a peak during PID-3 to−6, showing
a pattern similar to that of MCP-1 (Fig. 2 and Fig. 5a). In contrast,
TIMP-1 levels in serum after IAV-infection continuously increased
during the 9-day experimental period (Fig. 6b). Oral administration of
clarithromycin signiﬁcantly suppressed the induction of MCP-1 at PID-6
in serum, and induction of MMP-9 in the lungs and heart at PID-6 and in
serum at PID-3 (Fig. 2 and Fig. 5a). These results suggest that
Fig. 5. Clarithromycin (CAM) suppresses induction of MMP-9 in serum, heart and lungs
of mice infected with PR8. (a) MMP-9 levels in serum of infected mice treated with CAM
(solid bars) and MC (open bars) at PID-3, −6 and −9 and non-infected control at day 0
(n= 5, each group) measured by ELISA. Data are mean ± SD. (b) MMP-9 expression
levels in the lungs and heart of mice treated with CAM (+, solid bars) and MC (-, open
bars) at PID-3, −6, and −9 and uninfected control (day 0) (n= 5, each group) were
analyzed by western immunoblotting. 50 μg protein/lane. β-actin as an internal control.
Image J software was used to quantify the band intensities. Top panels of western im-
munoblotting show representative results of ﬁve experiments. *P < 0.05, **P < 0.01,
versus MC (by Student’s t-test).
Fig. 6. Eﬀects of clarithromycin (CAM) on lung trypsin levels and serum TIMP-1 in mice
infected with PR8. (a) Trypsin levels were measured in the supernatants of lung homo-
genates of mice treated with CAM and vehicle MC at PID-3, −6, and −9 and uninfected
control (n= 5, each group) by ELISA. Data are mean ± SD. (b) Serum TIMP-1 levels at
PID-3, −6, and −9 and uninfected control measured by ELISA. Data are mean ± SD.
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clarithromycin suppressed MCP-1 induction, resulting in the inhibition
of monocytes/macrophages accumulation and MMP-9 induction at in-
ﬂammation sites in the lungs and heart. MMP-9 preferentially degrades
type IV collagen in the basement membrane of blood vessels, resulting
in vascular hyperpermeability [17–20]. Therefore, clarithromycin also
signiﬁcantly suppressed Evans’ blue extravasation (Fig. 4C) in the lungs
and heart at PID-3 and/or−6, similar to the time courses of MCP-1 and
MMP-9 suppression.
The production of MMPs and MCP-1 is enhanced by transcriptional
factors NF-κB and AP-1 [11,12,35]. Clarithromycin inhibit NF-κB and
AP-1 binding to the promoters of target genes, resulting in suppression
of the transcription [36]. Our ﬁndings of clarithromycin-induced sup-
pression of MMP-9 and MCP-1 and accumulation of inﬂammatory cells
in the infected loci may add support to the above ﬁndings.
In the present study, we used Balb/C mice with a Th2 biased im-
mune response [37–39], in a series of study on immunomodulatory
eﬀects of clarithromycin [28]. Further studies in C57BL/6 mice with a
more Th1 dominated immune response are required. In addition, our
study indicates that clarithromycin treatment requires 3–6 days to
reach a clear suppression eﬀect on MMP-9 and MCP-1 and the ﬁnding
was supported by the previous report in rat autoimmune myocarditis
[40]. Further study on pre-administration of clarithromycin could
better deﬁne its eﬀects on IAV infection.
5. Conclusions
In addition to the marked immunomodulatory eﬀects of clari-
thromycin reported previously [26–28], including enhancement of se-
cretory IgA production, and its neutralizing activities and ability to
reduce re-infection rate in pediatric patients, the present study showed
that clarithromycin suppressed the inductions of MCP-1, MMP-9, in-
ﬂammatory cell accumulation, and vascular hyperpermeability in the
lungs and heart of mice infected with PR8. Although the anti-in-
ﬂammatory eﬀects of clarithromycin were transient; occurring mainly
during PID-3 to−6 at the early phase of infection, our results may add
support to the practice of clarithromycin use in the treatment of IAV
progression.
Acknowledgment
The authors thank Yukari Tominaga for the excellent technical
support.
References
[1] A.S. Lipatov, E.A. Govorkova, R.J. Webby, H. Ozaki, M. Peiris, Y. Guan, L. Poon,
R.G. Webster, Inﬂuenza: emergence and control, J. Virol. 78 (2004) 8951–8959.
[2] H.W. Kim, C.D. Brandt, J.O. Arrobio, B. Murphy, R.M. Chanock, R.H. Parrott,
Inﬂuenza A and B virus infection in infants and young children during the years
1957–1976, Am. J. Epidemiol. 109 (1979) 464–479.
[3] G. Chowell, S. Echevarria-Zuno, C. Viboud, L. Simonsen, M.A. Miller, I. Femández-
Gárate, C. González-Bonilla, V.H. Borja-Aburto, Epidemiological characteristics and
underlying risk factors for mortality during the autumn 2009 pandemic wave in
Mexico, PLoS One 7 (2012) e41069.
[4] L.E. Perkins, D.E. Swayne, Pathobiology of A/chicken/Hong Kong/220/97 (H5N1)
avian inﬂuenza virus in seven gallinaceous species, Vet. Pathol. 38 (2001) 149–164.
[5] S. Wang, T.Q. Le, N. Kurihara, J. Chida, Y. Cisse, M. Yano, H. Kido, Inﬂuenza virus-
cytokine-protease cycle in the pathogenesis of vascular hyperpermeability in severe
inﬂuenza, J. Infect. Dis. 202 (2010) 991–1001.
[6] H.Y. Pan, H. Yamada, J. Chida, S. Wang, M. Yano, M. Yao, J. Zhu, H. Kido, Up-
regulation of ectopic trypsins in the myocardium by inﬂuenza A virus infection
triggers acute myocarditis, Cardiovasc. Res. 89 (2011) 595–603.
[7] H. Kido, Inﬂuenza virus pathogenicity regulated by host cellular proteases cytokines
and metabolites, and its therapeutic options, Proc. Jpn. Acad. Ser. B. Phys. Biol. Sci.
91 (2015) 351–368.
[8] I.L. Indalao, T. Sawabuchi, E. Takahashi, H. Kido, IL-1β is a key cytokine that in-
duces trypsin upregulation in the inﬂuenza virus-cytokine-trypsin cycle, Arch.
Virol. 162 (2016) 201–211.
[9] A.H. Spraque, R.A. Khalil, Inﬂammatory cytokines in vascular dysfunction and
vascular disease, Biochem. Pharmacol. 78 (2009) 539–552.
[10] K. Yamane, I.L. Indalao, J. Chida, Y. Yamamoto, M. Hanawa, H. Kido,
Diisopropylamine dichloroacetate, a novel pyruvate dehydrogenase kinase 4
inhibitor, as a potential therapeutic agent for metabolic disorders and multiorgan
failure in severe inﬂuenza, PLoS One 9 (2014) e98032.
[11] A. Hozumi, Y. Nishimura, T. Nishimura, Y. Kotani, M. Yokoyama, Induction of
MMP-9 in normal human bronchial epithelial cells by TNF-alpha via NF-kappa B-
mediated pathway, Am. J. Physiol. Lung Cell Mol. Physiol. 281 (2001) L1444–1452.
[12] S.J. Suh, U.H. Jin, H.J. Choi, H.W. Chang, J.K. Son, S.H. Lee, S.J. Jeon, K.H. Son,
Y.C. Chang, Y.C. Lee, C.H. Kim, Cryptotanshinone from Salvia miltiorrhiza BUNGE
has an inhibitory eﬀect on TNF-alpha-induced matrix metalloproteinase-9 produc-
tion and HASMC migration via down-regulated NF-kappa B and AP-1, Biochem.
Pharmacol. 71 (2006) 1680–1689.
[13] H.D. Klenk, R. Rott, M. Orlich, J. Blödom, Activation of inﬂuenza A viruses by
trypsin treatment, Virology 68 (1975) 426–439.
[14] H. Kido, Y. Okumura, H. Yamada, T.Q. Le, M. Yano, Proteases essential for human
inﬂuenza virus entry into cells and their inhibitors as potential therapeutic agents,
Curr. Pharm. Des. 13 (2007) 405–414.
[15] H. Kido, Y. Okumura, E. Takahashi, H.P. Pan, S. Wang, D. Yao, M. Yao, J. Chida,
M. Yano, Role of host cellular proteases in the pathogenesis of inﬂuenza and in-
ﬂuenza-induced multiple organ failure, Biochim. Biophys. Acta 1824 (2012)
186–194.
[16] Q.X. Niu, H.Q. Chen, Z.Y. Chen, Y.L. Fu, J.L. Lin, S.H. He, Induction of in-
ﬂammatory cytokine release from human umbilical vein endothelial cells by ago-
nists of proteinase-activated receptor-2, Clin. Exp. Pharmacol. Physiol. 35 (2008)
89–96.
[17] D. Westermann, K. Savvatis, H.P. Schultheiss, C. Tscöpe, Immunomodulation and
matrix metalloproteinases in viral myocarditis, J. Mol. Cell Cardiol. 48 (2010)
468–473.
[18] H.S. Rosário, S.W. Waldo, S.A. Becker, G.W. Schmid-Schönbein, Pancreatic trypsin
increases matrix metalloproteinase-9 accumulation and activation during acute
intestinal ischemia-reperfusion in the rat, Am. J. Pathol. 164 (2004) 1707–1716.
[19] E. Koivunen, A. Ristimäki, O. Itkonen, S. Osman, M. Vuento, U.H. Stenman, Tumor-
associated trypsin participates in cancer cell-mediated degradation of extracellular
matrix, Cancer Res. 51 (1991) 2107–2112.
[20] A. Rosell, A. Ortega-Aznar, J. Alvarez-Sabin, I. Fernández-Cadenas, M. Ribo,
C.A. Molina, E.M. Lo, J. Montaner, Increased brain expression of matrix metallo-
proteinase-9 after ischemic and hemorrhagic human stroke, Stroke 37 (2006)
1399–1406.
[21] S. Kudoh, T. Uetake, K. Hagiwara, M. Hirayama, L.H. Hus, H. Kimura, Y. Sugiyama,
Clinical eﬀects of low-dose long-term erythromycin chemotherapy on diﬀuse pan-
bronchiolitis, Nihon Kyobu Shikkan Gakkai Zasshi 25 (1987) 632–642.
[22] T. Ichiyama, M. Nishikawa, T. Yoshitomi, S. Hasegawa, T. Matsubara, T. Hayashi,
S. Furukawa, Clarithromycin inhibits NF-kappaB activation in human peripheral
blood mononuclear cells and pulmonary epithelial cells, Antimicrob. Agents
Chemother. 45 (2001) 44–47.
[23] M.T. Labro, Anti-inﬂammatory activity of macrolides: a new therapeutic potential?
Antimicrob. Agents Chemother. 41 (1998) 37–46.
[24] L. Amado-Rodríguez, A. González-López, I. López-Alonso, A. Aguirre, A. Astudillo,
E. Batalla-Solís, J. Blazquez-Prieto, E. García-Prieto, G.M. Albaiceta, Anti-in-
ﬂammatory eﬀects of clarithromycin in ventilator-induced lung injury, Respir. Res.
14 (2013) 52.
[25] H. Takizawa, M. Desaki, T. Ohtoshi, S. Kawasaki, T. Kohyama, M. Sato, M. Tanaka,
T. Kasama, K. Kobayashi, J. Nakajima, K. Ito, Erythromycin modulates IL-8 ex-
pression in normal and inﬂamed human bronchial epithelial cells, Am. J. Respir.
Crit. Care Med. 156 (1997) 266–271.
[26] T. Sawabuchi, S. Suzuki, K. Iwase, C. Ito, D. Mizuno, H. Togari, I. Watanabe,
S.R. Talukder, J. Chida, H. Kido, Boost of mucosal secretory immunoglobulin A
response by clarithromycin in paediatric inﬂuenza, Respirology 14 (2009)
1173–1179.
[27] W. Shinahara, E. Takahashi, T. Sawabuchi, M. Arai, N. Hirotsu, Y. Takasaki,
S. Shindo, K. Shibao, T. Yokoyama, K. Nishikawa, M. Mino, M. Iwaya, Y. Yamashita,
S. Suzuki, D. Mizuno, H. Kido, Immunomodulator clarithromycin enhances mucosal
and systemic immune responses and reduces re-infection rate in pediatric patients
with inﬂuenza treated with antiviral neuraminidase inhibitors: a retrospective
analysis, PLoS One 8 (2013) e70060.
[28] E. Takahashi, K. Kataoka, I.L. Indalao, K. Konoha, K. Fujii, J. Chida, D. Mizuno,
K. Fujihashi, H. Kido, Oral clarithromycin enhances airway immunoglobulin A
(IgA) immunity through induction of IgA class switching recombination and B-cell-
activating factor of the tumor necrosis factor family molecule on mucosal dendritic
cells in mice infected with inﬂuenza A virus, J. Virol. 86 (2012) 10924–10934.
[29] I.H. Sarelius, A.J. Glading, Control of vascular permeability by adhesion molecules,
Tissue Barriers 3 (2015) e985954.
[30] D. Yao, M. Kuwajima, Y. Chen, M. Shiota, Y. Okumura, H. Yamada, H. Kido,
Impaired long-chain fatty acid metabolism in mitochondria causes brain vascular
invasion by a non-neurotropic epidemic inﬂuenza A virus in the newborn/suckling
period: implications for inﬂuenza-associated encephalopathy, Mol. Cell Biochem.
299 (2007) 85–92.
[31] Y. Nezu, K. Hagiwara, Y. Yamamoto, T. Fujiwara, K. Matsuo, A. Yoshida, A. Kawai,
T. Saito, T. Ochiya, miR-135b, a key regulator of malignancy, is linked to poor
prognosis in human myxoid liposarcoma, Oncogene 157 (2016) 1–12.
[32] C.A. Dinarello, A. Simon, J.W. van der Meer, Treating inﬂammation by blocking
interleukin-1 in a broad spectrum of diseases, Nat. Rev. Drug Discov. 11 (2012)
633–652.
[33] G. Chowell, S. Echevarría-Zuno, C. Viboud, L. Simonsen, M.A. Miller, I. Femández-
Gárate, C. González-Bonilla, V.H. Borja-Aburto, Epidemiological characteristics and
underlying risk factors for mortality during theautumn 2009 pandemic wave in
Mexico, PLoS One 7 (2012) e41069.
[34] M. Hiyoshi, I.L. Indalao, M. Yano, K. Yamane, E. Takahashi, H. Kido, Inﬂuenza A
E. Takahashi et al. Comparative Immunology, Microbiology and Infectious Diseases 56 (2018) 6–13
12
virus infection of vascular endothelial cells induces GSK-3β-mediated β-catenin
degradation in adherens junctions, with a resultant increase in membrane perme-
ability, Arch. Virol. 160 (2015) 225–234.
[35] K. Hacke, B. Rincon-Orozco, G. Buchwalter, S.Y. Siehler, B. Wasylyk, L. Wiesmüller,
F. Rösl, Regulation of MCP-1 chemokine transcription by p53, Mol. Cancer 9
(2010) 82.
[36] T. Kikuchi, K. Hagiwara, Y. Honda, K. Gomi, H. Kobayashi, Y. Tokue, A. Watanabe,
T. Nukiwa, Clarithromycin suppresses lipopolysaccharide-induced interleukin-8
production by human monocytes through AP-1 and NF-κB transcription factors, J.
Antimicrob. Chemother. 49 (2002) 745–755.
[37] N. Jovicic, I. Jeftic, I. Jovanovic, G. Radosavljevic, N. Arsenijevic, M.L. Lukic,
N. Pejnovic, Diﬀerential immunometabolic phenotype in Th1 and Th2 dominant
mouse strains in response to high-fat feeding, PLoS One 28 (7) (2015)
e0134089 (10).
[38] F.P. Heinzel, M.D. Sadick, B.J. Holaday, R.L. Coﬀman, R.M. Locksley, Reciprocal
expression of interferon gamma or interleukin 4 during the resolution or progres-
sion of murine leishmaniasis. Evidence for expansion of distinct helper T cell sub-
sets, J. Exp. Med. 169 (1989) 59–72.
[39] C.D. Mills, K. Kincaid, J.M. Alt, M.J. Heilman, A.M. Hill, M-1/M-2 macrophages and
the Th1/Th2 paradigm, J. Immunol. 164 (2000) 6166–6173.
[40] K. Hishikari, R. Watanabe, M. Ogawa, J. Suzuki, M. Masumura, T. Shimizu,
K. Takayama, Y. Hirata, R. Nagai, M. Isobe, Early treatment with clarithromycin
attenuates rat autoimmune myocarditis via inhibition of matrix metalloproteinase
activity, Heart 96 (7) (2010) 523–527.
E. Takahashi et al. Comparative Immunology, Microbiology and Infectious Diseases 56 (2018) 6–13
13
